STAT

STAT+: Pharmalittle: We’re reading about a setback for Eyepoint, a win for Amylyx, and more

STAT+: Pharmalittle: We’re reading about a setback for Eyepoint, a win for Amylyx, and moreWorldPing

Eyepoint disclosed that a Phase 3 trial of its experimental treatment for a common cause of age-related blindness fell short of its primary goal…

This is a short WorldPing brief. The full report was published by STAT.

Read the full report at STAT

Related news

STAT+: Amylyx endocrine drug succeeds in pivotal studyWorldPing
STAT

STAT+: Amylyx endocrine drug succeeds in pivotal study

In a Phase 3 trial of people with post-bariatric hypoglycemia, those taking the drug, avexitide, experienced a 55% reduction in the rate of serious low blood sugar events compared with…

Brief by WorldPing · Original reporting by STAT

ESPN

Agent: Nats' Abrams 'not thrilled' about 2B move

CJ Abrams is "not thrilled" about moving to second base for the Nationals, his agent said, but "his priority is to win games ... and to be a team-first player."…

Brief by WorldPing · Original reporting by ESPN

Deutsche Welle

Should India be worried about the Mecca defense pact?

A defense agreement between Pakistan, Saudi Arabia and Turkey brings Islamabad deeper into the security architecture of the Middle East. How is India planning to respond?

Brief by WorldPing · Original reporting by Deutsche Welle